InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.185 -0.59 (-76.13%)+
Announcement
Release
16 Jan 2026 8:22AM
Price at Release
$0.775
Full Release
download
Summary
Proteomics International Laboratories Ltd, a leader in precision diagnostics, announced the securing of a Canadian patent for its proprietary PromarkerEso blood test, designed for the early diagnosis of esophageal adenocarcinoma (EAC). The granted patent offers intellectual property protection in Canada until 2035 and supports future commercial pathways in North America. PromarkerEso, which combines glycoproteins with clinical factors to assess the risk of EAC, addresses a significant unmet need in timely diagnosis of the disease. The test has shown high accuracy in clinical studies and patent protection extends to various jurisdictions including Australia, Europe, and the USA.
Key Points
  • Proteomics International Laboratories Ltd (ASX: PIQ) secured a Canadian patent for its PromarkerEso test for esophageal adenocarcinoma (EAC).
  • The patent provides intellectual property protection in Canada until 17 November 2035.
  • PromarkerEso is a first-in-class blood test utilizing biomarkers to assess the risk of EAC.
  • The test combines four key serum glycoproteins with patient clinical factors to generate a risk score for EAC.
  • EAC represents a significant global health challenge with a five-year survival rate of less than 20%.
  • The patent supports future commercial opportunities in North America, including direct sales and licensing.
  • The test has demonstrated high accuracy in clinical studies for early EAC detection.
  • Patent protection for PromarkerEso extends to multiple jurisdictions including Australia, China, Europe, and the USA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.